• 2 November 2017

    Incyte and AstraZeneca to begin Phase III trial for NSCLC

    Incyte has partnered with AstraZeneca’s biologics research and development division MedImmune to evaluate the combination of epacadostat and Imfinzi (durvalumab) in a Phase III clinical trial to treat non-small cell...

  • 19 October 2017

    Acticor Biotech to assess ACT017 in Phase I trial

    French biotechnology firm Acticor Biotech has entered an agreement to study Dutch Authorities' investigational drug candidate ACT017 in a Phase I clinical trial with healthy subjects.